Clinical Trials
5
Active:0
Completed:5
Trial Phases
4 Phases
Phase 1:1
Phase 2:1
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (40.0%)Not Applicable
1 (20.0%)Phase 1
1 (20.0%)Phase 2
1 (20.0%)A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Lupus Erythematosus, CutaneousLupus Erythematosus, Systemic
- Interventions
- Drug: 1 mg/kg CNTO 136Drug: 4 mg/kg CNTO 136Drug: 10 mg/kg CNTO 136Drug: Placebo
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01702740
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00992186
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 1230
- Registration Number
- NCT00307437
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT00267969
News
No news found